| Original language | English (US) |
|---|---|
| Pages (from-to) | 1548-1549 |
| Number of pages | 2 |
| Journal | CHEST |
| Volume | 139 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2011 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
}
TY - JOUR
T1 - Response
AU - Chung, Lorinda
AU - Liu, Juliana
AU - Parsons, Lori S.
AU - Hassoun, Paul M.
AU - McGoon, Michael D.
AU - Badesch, David B.
AU - Miller, Dave P.
AU - Nicolls, Mark R.
AU - Zamanian, Roham T.
N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Chung has received research support funding from Gilead Sciences and United Therapeutics Corp and has served on the speakers' bureau for Actelion Pharmaceuticals (< $10,000 per year). Ms Liu has served as a consultant to Gilead Sciences and United Therapeutics Corp and participated in advisory board meetings for Actelion Pharmaceuticals. Ms Parsons and Mr Miller are employees of ICON Clinical Research, a company that receives research funding from Actelion and other pharmaceutical companies. Dr Hassoun has received research funding support from Actelion/CoTherix Inc and is on the Advisory Board for Novartis. Dr McGoon has received research funding from Gilead and Medtronic Inc. He has served on steering committees for Gilead and Lung Rx Inc and participated on clinical end point committees in studies sponsored by Actelion. He is on a Data Safety Monitoring Board for a study sponsored by Gilead. Dr McGoon has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Badesch has received honoraria for service on steering committees and/or advisory boards for Actelion/CoTherix, Gilead/Myogen Inc, Encysive Pharmaceuticals, Pfizer Inc, GlaxoSmithKline, Lung Rx Inc, United Therapeutics, Eli Lilly and Company/ICOS, Biogen Idec Inc, mondoBIOTECH AG/mondoGEN AG, and Bayer. Dr Badesch has received grants from Actelion/CoTherix, Gilead/Myogen Inc, Encysive Pharmaceuticals, Pfizer Inc, United Therapeutics, Lung Rx Inc, Eli Lilly and Company/ICOS, Bayer, Novartis, and National Institutes of Health/National Heart, Lung, and Blood Institute. Dr Badesch has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Zamanian has received research funding support through the Entelligence-Actelion career development research grant ($75,000) and has served as a consultant to United Therapeutics and Gilead pharmaceuticals. Dr Nicolls has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2011/6/1
Y1 - 2011/6/1
UR - http://www.scopus.com/inward/record.url?scp=79958704507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958704507&partnerID=8YFLogxK
U2 - 10.1378/chest.11-0341
DO - 10.1378/chest.11-0341
M3 - Letter
AN - SCOPUS:79958704507
SN - 0012-3692
VL - 139
SP - 1548
EP - 1549
JO - CHEST
JF - CHEST
IS - 6
ER -